Similarly, IL6 is under investigation for biomarker potential, and blockade of its receptor evaluated in MG in a phase 3 Satralizumab (IL6 receptor mAb) trial although at time of writing, this trial had been halted (Table 1). The gene discussed is IL6; the disease is myasthenia gravis.